Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
ImmuNext logo — ImmuNext develops compounds on the cutting edge of immunothe...

ImmuNext

ImmuNext develops compounds on the cutting edge of immunotherapy for cancer and autoimmune diseases.

Founded 2011 4 employees Biotechnology

General Information

Company Name ImmuNext
Founded Year 2011
Employees 4
Industries Biotechnology
Social

Get notified when ImmuNext moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About ImmuNext

ImmuNext is a biotechnology startup founded in 2011, focusing on the development of innovative compounds in the field of immunotherapy for cancer and autoimmune diseases. The company's slogan "ImmuNext develops compounds on the cutting edge of immunotherapy for cancer and autoimmune diseases." emphasizes their commitment to pioneering immunotherapy solutions. ImmuNext is dedicated to the development of immune-based therapeutics for various immune-related disorders, including autoimmunity, cancer, transplantation rejection, and infectious diseases. Their approach involves targeting critical immunomodulatory molecules to restore immune homeostasis and cure diseases. ImmuNext has several significant assets in their portfolio, including an Immunometabolic Checkpoint Target, Anti-VISTA for cancer treatment, VISTA agonists for autoimmune diseases, and re-engineered Anti-CD40L antagonists for autoimmunity and graft rejection. These assets represent the company's focus on leveraging antibody-based therapeutics to target newly identified molecules, showing potential for disease remission. ImmuNext has also engaged in strategic partnerships with renowned companies such as Eli Lilly, Johnson and Johnson subsidiary - Janssen Biotech, Hoffman-La Roche, and Sanofi to advance their research and development efforts. ImmuNext's core competencies lie in discovery, target biology, and pre-clinical drug development, positioning them as a significant player in the biotechnology industry. With a robust portfolio and strategic collaborations, ImmuNext is well-positioned to make significant contributions to the advancement of immunotherapy. For more information about ImmuNext and their portfolio, interested parties can visit their website: http://immunext.com/portfolio/ and explore career opportunities at: http://immunext.com/careers/.

Taxonomy: Immunotherapy, Cancer treatment, Autoimmune disease treatment, Therapeutics, Immune-based compounds, Immunomodulatory molecules, Antibody-based therapeutics, Drug development, Immunometabolic checkpoint target, VISTA antagonist, VISTA agonist, Anti-CD40L antibodies, Pharmaceuticals

No funding data available for ImmuNext yet.

Get notified when ImmuNext raises funding

FAQ About ImmuNext

ImmuNext develops compounds on the cutting edge of immunotherapy for cancer and autoimmune diseases.
ImmuNext was founded in 2011.
ImmuNext operates in the following industries: Biotechnology.
ImmuNext has approximately 4 employees.

We're actively collecting intelligence on ImmuNext.

Track ImmuNext to get notified

Don't just browse. Track.

Signal Tracker monitors ImmuNext and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy